In Brief: FDA Biological Response Modifiers Committee
This article was originally published in The Gray Sheet
Executive Summary
FDA Biological Response Modifiers Committee: Slated to meet Feb. 28 and 29 at the Holiday Inn in Bethesda, Maryland. On Feb. 28 the committee will discuss a premarket approval application for CellPro's Ceprate SC device for selection of CD34+ progenitor/stem cells and receive an update on "stem cell policy," according to a Jan. 31 notice in the Federal Register. On Feb. 29 the committee will discuss issues in early clinical trial development for in utero stem cell transplantation and the draft addendum to the 1991 points-to-consider on human somatic cell and gene therapy. Contact FDA's William Freas or Pearline Muckelvgene, 301/827-0314...
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: